🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Jupiter Life Line Hospitals Limited JLHL NSEPHARMA

Healthcare · Medical Care Facilities · India
https://www.jupiterhospital.com
Company Profile ↓
₹286.45
+1.07% 1Y
Mkt Cap₹9,390.69 Cr
P/E48.40
P/B1.36
Div. Yield0.06%
52W High₹332.40
52W Low₹239.80
Book Value₹47.10
EPS (TTM)₹5.92

Company Overview

Jupiter Life Line Hospitals Limited, a multi-specialty hospital, provides health care services under the Jupiter brand in India. The company offers treatments in the areas of bariatric surgery, breast care center, cardiac surgery, cardiology, chest medicine, dental care, dermatology, endocrinology and diabetes, ENT, gastroenterology, general surgery and minimal access surgery, hematology and BMT, HPB and surgical gastroenterology, infectious diseases, internal medicine, interventional radiology, mental health, nephrology, neurology, neurosurgery, nutrition and dietetics, Obs and gynecology, oncology, ophthalmology, organ transplant, orthopedics, pediatrics, pain clinic, plastic and cosmetic surgery, rehabilitation, rheumatology, robotic knee replacement, robotic surgery, TAVI/TAVR, and urology. It also operates hotel under the Fortune Park Lake City Hotel brand in Thane. The company was incorporated in 2002 and is based in Mumbai, India.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 38.6% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 18.9% CAGR over the past five years.

Healthy Margins

Operating margin of 17.2% supports profitability.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.38.

Recent Developments

  • Mar 2026 Revenue of ₹1,498.49 Cr (+15.2% YoY); net profit ₹194.01 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +15.2%, earnings +0.4%.
  • 5-Year Trend Long-term compounding — revenue CAGR 18.9%, profit CAGR 38.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:18.85%
1 Year:15.15%

Compounded Profit Growth

5 Years:38.58%
1 Year:0.42%

Stock Price Performance

1 Year:+1.07%
6 Months:+13.69%
3 Months:+7.16%
1 Month:-10.27%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 50% of range
₹239.80 ₹332.40
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)33.83 · Neutral
Price Performance
1M-10.27%
3M+7.16%
6M+13.69%
1Y+1.07%
Valuation vs Sector

P/E of 48.40 is above the sector median of 41.64 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 18.9% over 5 years.
  • Profit CAGR of 38.6% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
48.40
Industry PE
41.64
Forward P/E
34.95
PEG Ratio
-
Book Value
₹47.10
Price to Book
1.36
P/S
6.74
EV/EBITDA
32.28
Dividend Yield
0.06%

Growth (CAGR)

Revenue 5Y
18.85%
Profit 5Y
38.58%
Revenue (YoY)
15.15%
Earnings (YoY)
0.42%

Profitability & Returns

ROCE
13.34%
ROE
12.56%
ROA
8.14%
Profit Margin
12.95%
Op Margin
17.18%
Gross Margin
78.86%
EPS (Latest Qtr)
₹1.14
EPS (TTM)
₹5.92

Balance Sheet & Liquidity

Debt/Equity
0.38
Quick Ratio
2.85
Current Ratio
3.02
Debt
₹584.24 Cr
Total Assets
₹2,383.13 Cr
Current Assets
₹684.90 Cr
Working Capital
₹458.32 Cr

Ownership

Promoter Holding
66.87%
Chg in Prom Hold
-0.14%
FII / Inst Holding
23.45%
Chg in FII Hold
2.53%

Financial Snapshot

Enterprise Value
₹9,390.69 Cr
Total Revenue (TTM)
₹1,498.49 Cr
EBITDA
₹375.38 Cr
Free Cash Flow
₹-234.14 Cr
Operating Cash Flow
₹267.71 Cr
Shares Outstanding
₹32.78 Cr
Gross Margin
78.86%
Payout Ratio
3.49%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 JLHL Jupiter Life Line Hospitals Limited NSEPHARMA 286.45 48.40 ₹9,390.69 Cr 0.06% 13.34% 12.56% 18.85% 38.58%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,899.00 39.73 ₹4.56 L Cr 0.82% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,100.00 94.06 ₹2.42 L Cr 0.36% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,857.00 75.99 ₹1.64 L Cr 0.77% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,650.00 64.10 ₹1.24 L Cr 0.22% 19.20% 20.48% 14.85% 33.34%
6 LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA 684.90 236.17 ₹1.19 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,120.00 22.36 ₹1.13 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,385.00 28.85 ₹1.12 L Cr 0.88% 14.86% 11.27% 7.23% 11.45%
9 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 1,840.00 111.85 ₹99,333.61 Cr 0.13% 19.53% 16.77% 3.77% 4.00%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue 242.00 Cr243.00 Cr263.00 Cr273.00 Cr291.00 Cr289.00 Cr335.00 Cr333.00 Cr336.66 Cr352.95 Cr393.63 Cr365.37 Cr387.84 Cr410.98 Cr
Cost of Revenue --------67.41 Cr132.44 Cr73.76 Cr69.04 Cr73.74 Cr154.51 Cr
Gross Profit --------269.26 Cr220.51 Cr319.87 Cr296.32 Cr314.10 Cr256.47 Cr
Operating Expenses 191.00 Cr190.00 Cr202.00 Cr211.00 Cr228.00 Cr223.00 Cr257.00 Cr256.00 Cr207.21 Cr163.31 Cr249.09 Cr234.60 Cr248.19 Cr203.64 Cr
Operating Income 42.00 Cr42.00 Cr50.00 Cr51.00 Cr53.00 Cr54.00 Cr64.00 Cr62.00 Cr62.05 Cr57.20 Cr70.79 Cr61.73 Cr65.91 Cr52.83 Cr
EBITDA 52.00 Cr53.00 Cr61.00 Cr62.00 Cr63.00 Cr65.00 Cr78.00 Cr76.00 Cr86.58 Cr91.24 Cr103.52 Cr86.16 Cr99.82 Cr89.86 Cr
Interest Expense 11.00 Cr12.00 Cr12.00 Cr1.00 Cr1.00 Cr1.00 Cr1.00 Cr3.00 Cr5.61 Cr8.27 Cr7.84 Cr7.55 Cr9.01 Cr12.86 Cr
Pretax Income 32.00 Cr34.00 Cr41.00 Cr58.00 Cr62.00 Cr60.00 Cr70.00 Cr67.00 Cr63.32 Cr61.75 Cr74.22 Cr56.91 Cr67.56 Cr50.55 Cr
Tax Provision 16.32 Cr-20.40 Cr7.79 Cr14.50 Cr16.74 Cr15.60 Cr18.20 Cr14.74 Cr18.04 Cr17.80 Cr16.75 Cr14.41 Cr17.29 Cr13.04 Cr
Net Income 16.00 Cr54.00 Cr34.00 Cr44.00 Cr45.00 Cr45.00 Cr52.00 Cr52.00 Cr44.00 Cr43.89 Cr57.48 Cr42.55 Cr50.62 Cr37.49 Cr
Diluted EPS 2.799.555.146.666.876.787.887.946.891.341.751.101.531.14

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 463.00 Cr486.00 Cr-892.54 Cr1,069.50 Cr1,301.32 Cr1,498.49 Cr
Cost of Revenue ---181.15 Cr214.01 Cr282.42 Cr316.85 Cr
Gross Profit ---711.39 Cr855.49 Cr1,018.90 Cr1,181.64 Cr
Operating Expenses 379.00 Cr419.00 Cr-547.58 Cr657.28 Cr772.46 Cr924.22 Cr
Operating Income 58.00 Cr36.00 Cr-163.81 Cr198.21 Cr246.45 Cr257.42 Cr
EBITDA 84.00 Cr67.00 Cr-206.01 Cr260.46 Cr321.18 Cr375.38 Cr
Interest Expense 26.00 Cr39.00 Cr-38.74 Cr22.66 Cr3.42 Cr27.31 Cr
Pretax Income 33.00 Cr2.00 Cr-128.71 Cr195.41 Cr260.68 Cr260.44 Cr
Tax Provision 3.30 Cr4.96 Cr-55.80 Cr18.80 Cr66.92 Cr66.25 Cr
Net Income 30.00 Cr-2.00 Cr-72.91 Cr176.61 Cr193.20 Cr194.01 Cr
Diluted EPS 5.83-0.45-2.225.695.895.92

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 603.00 Cr789.00 Cr-985.53 Cr1,281.33 Cr1,935.75 Cr2,383.13 Cr
Current Assets ---209.26 Cr409.76 Cr692.54 Cr684.90 Cr
Cash & Equivalents ---134.46 Cr23.01 Cr92.52 Cr54.76 Cr
Inventory ---19.00 Cr21.34 Cr26.46 Cr38.34 Cr
Receivables ---45.69 Cr57.21 Cr43.23 Cr75.54 Cr
Total Liabilities ---621.62 Cr112.59 Cr579.45 Cr839.04 Cr
Current Liabilities ---132.14 Cr105.75 Cr158.39 Cr226.57 Cr
Long Term Debt ---452.51 Cr0321.75 Cr500.90 Cr
Total Debt 272.00 Cr426.00 Cr-468.63 Cr0393.14 Cr584.24 Cr
Total Equity 237.00 Cr239.00 Cr-365.69 Cr1,169.04 Cr1,356.24 Cr1,544.08 Cr
Shares Outstanding ---32.78 Cr32.78 Cr32.78 Cr32.78 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 74.00 Cr123.00 Cr-117.17 Cr114.52 Cr266.74 Cr267.71 Cr
Investing Cash Flow -43.00 Cr-295.00 Cr--103.57 Cr-246.14 Cr-497.33 Cr-441.93 Cr
Financing Cash Flow -32.00 Cr184.00 Cr-17.50 Cr128.16 Cr296.70 Cr136.47 Cr
Capital Expenditure -28.00 Cr-241.00 Cr--77.24 Cr-85.30 Cr-327.59 Cr-501.85 Cr
Free Cash Flow 46.00 Cr-118.00 Cr-39.92 Cr29.23 Cr-60.85 Cr-234.14 Cr
Net Change in Cash -1.00 Cr12.00 Cr-31.10 Cr-3.47 Cr66.11 Cr-37.76 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % ---79.7%80.0%78.3%78.9%
Operating Margin % 12.5%7.4%-18.4%18.5%18.9%17.2%
Net Margin % 6.5%-0.4%-8.2%16.5%14.8%12.9%
ROE % 12.7%-0.8%-19.9%15.1%14.2%12.6%
ROCE % ---19.2%16.9%13.9%11.9%

Shareholding Pattern

Insiders
66.87%
Institutions
23.45%
Public Float
70.78%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for JLHL

Google News Wed, 02 Sep 2026

JLHL Stock Slides As Momentum Traders Hunt Support - StocksToTrade

<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxQT3VFN09XTllSWmFNdTdvaDNrVTVaTXdzX2doQ0U0VjkybmQyQ0otUS1LWTcwTnNTbzBhYmtCM2hORzZDYzAyaHVQR1h2dFhsMHFwcVg4YzdySkhZZGl2ZWRqcnZQdUV0UG9ySFJkZ3ZuNjZmVGZ4SE1ZVGxoWnFOdg?oc=5" target="_…

Google News Wed, 02 Sep 2026

Which stocks are gapping on Wednesday? - ChartMill

<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxNTm5rQzhqcHgtaWpzOWE1ZHJ2T21Uakk1LWc0S0tTZ2FKdXBUb0Nad3pUNGUybDI1MXdkby1HLVlvV3ptRnF5QnoyeDZfVVV2LVo0cXNjYmtUNWxxbkZWcHo5Y2JFYlJiem9MbXEtMXVTV1BUb2Q4UTRkVFhCOXBhRGdEOVBPSjFKUUd2YU…

Google News Mon, 24 Aug 2026

Julong Holding (JLHL) director reports zero share stake - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxPbmM1QmtIbTltalRtbER6OUxVTnc2UjlkM19RWkZ0Z2hyYy1ycFo1OW9sek1kOUcyWmhPWGNwMDFUak9STWlzRXdiRVVxZUNLRXRIdWZlUy02YlJSOS1NeXBuS3RRU3laSVdpTTN4ZXZ5eXQxNjh6ZjFQS0ZlaDBTcTZVcS1VellReWdyMn…

Google News Wed, 19 Aug 2026

Julong Holding (NasdaqCM:JLHL) Stock Revenue Growth Clashes With Margin Erosion - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxNbmNOZjZ2UzdYcnVBUGxsMnZubjNvRlR4aUtNWElidUxnV0JjSE1HS0hkQVlIcl9rbWRwRHN1UzFTR1B0cFdMQmNDeHlVRmtEOTFpdFJGZ3Y0NVZfcjRvczRRaXF5MldMbEh2d1V1Vk1IQlVZT19IcWJkdVBKMkZENFJqeFN4Mjdacy1TMT…

Google News Wed, 05 Aug 2026

Why Julong Holding Limited (JLHL) Stock Is Up Today - quiverquant.com

<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxNWmtlekliOEpaZFlub3ZySk9pemdzcEVhVXJHMVNia0ZFNkllMlJqTHdCc2YxV3FzUWNPaVlXVC0yNFBFTDVRNVEwbmFRZ3F2RDBhS2stTGNLajVhSlZ0RHMyZGVmdzRWc3NGWE1MMkEzQ3pVdW9XMHVaaEQtWEFDR2NWNEw4dWdNOFprNw…

Google News Wed, 02 Sep 2026

JLHL Stock Pulls Back As Volatility Attracts Active Traders - StocksToTrade

<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxQYnAwMDJBVVN2ekFUSFJGV1Q4Q21oQXJpU2JubkI5OGtuZ1lreVA1c2tBcXphWWRsT0dnWTg4ei1aV2dJYkY0R3RNRFktWk52Nm9xZEhLQ3NXTk41Q3BEM2gtWTFTSWhCcmZPUVZkSXZfaXoyRkd6ZEFwTHVNbENZdEV2RQ?oc=5" targe…

JLHL — Frequently Asked Questions

What is the current share price of Jupiter Life Line Hospitals Limited (JLHL)?

As of 2026-09-08 04:53 IST, Jupiter Life Line Hospitals Limited (JLHL) trades at ₹286.45 on NSE. Its 52-week range is ₹239.80 to ₹332.40.

What is the market capitalisation of JLHL?

Jupiter Life Line Hospitals Limited (JLHL) has a market capitalisation of ₹9,390.69 Cr on NSE.

What is the P/E ratio of JLHL?

JLHL trades at a trailing price-to-earnings (P/E) ratio of 48.40. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 1.36.

Does JLHL pay a dividend?

Jupiter Life Line Hospitals Limited (JLHL) currently offers a dividend yield of 0.06%.

What is the return on equity (ROE) of JLHL?

JLHL has a return on equity (ROE) of 12.56%. Its return on capital employed (ROCE) is 13.34%.

Is JLHL a good stock to buy?

This page provides a data-driven analysis of Jupiter Life Line Hospitals Limited (JLHL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space